PEDIATRICS Vol. 43 No. 2 February 1969, pp. 302-303
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Marks, J. F.
Right arrow Articles by Fink, C. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Marks, J. F.
Right arrow Articles by Fink, C. W.

Hypertensive Encephalopathy and Desoxycorticosterone

James F. Marks M.D.1 and Chester W. Fink M.D.1

1 Associate Professor of Pediatrics Department of Pediatrics University of Texas Southwwestern Medical School Dallas, Texas 75235

Doctor Monteleone reports a patient with congenital adrenal hyperplasia who had permanent severe neurologic sequellae following DOC-induced hypertensive encephalopathy. Since the preparation of our previous manuscript, we have seen three additional children who have suffered from mineralocorticoid-induced hypertension following the implantation of DOC pellets. Our experience would indicate that this complication of mineralocorticoid therapy is much more common than previously recognized.

The administration of some long-acting form of salt-retaining hormone is necessary in the infant with the salt-losing form of adrenal hyper plasia.